Abstract
Approaches to hereditary breast cancer testing are shifting as multi-gene panels become more widely available. This paper describes our center’s experience and outcomes of a 6-gene panel test as a first-tier approach in patients who were candidates for BRCA testing. Between July and December 2013, a 6-gene panel test was ordered for patients meeting criteria for BRCA testing. A retrospective review detailed the mutation and variant of uncertain significance (VUS) rates for the genes analyzed. The mutation rate was 5.2 % (n = 7) and the VUS rate was 6.7 % (n = 9). A subsequent review determined the number of BRCA-negative patients who would have been offered additional single gene testing had BRCA, only, been their first-tier test. Applying consensus criteria revealed 7.1 % (n = 9) cases that met criteria for additional testing. Pedigree analysis by a certified genetic counselor revealed 26.8 % (n = 34) cases that would have been offered additional testing based on personal and/or family history. Our results suggest that this panel may be warranted as a first-tier test for a small subset of patients, but likely represents over testing for the majority of patients who are candidates for BRCA testing. The genes selected for panels, the extra costs per patient and the chance of VUS must be considered before we uniformly switch from BRCA to full panel testing on all patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ambry Genetics. (2014). BRCAplus: A 6-gene hereditary breast cancer test. White Paper. http://www.ambrygen.com/sites/default/files/pdfs/forms/most_updated/cancer/BRCAPlus_While %20_Paper_0214.pdf. Accessed on June 11, 2014.
Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., & Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130. doi:10.1086/375033.
Arpino, G., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Research, 6(3), R149–R156. doi:10.1186/bcr767.
Association for Molecular Pathology v. Myriad Genetics, Inc., et al. (2013). 12–398.
Benusiglio, P. R., Malka, D., Rouleau, E., De Pauw, A., Buecher, B., Nogues, C., & Caron, O. (2013). CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics, 50(7), 486–489. doi:10.1136/jmedgenet-2012-101472.
Chen, W.Y., & Colditz, G.A. (2006). Patient information: Tamoxifen and raloxifene for the prevention of breast cancer. 14.2:7.
Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., & Feunteun, J. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:10.1054/bjoc.2000.1167.
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., & National Comprehensive Cancer, N. (2010). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network, 8(5), 562–594.
Daly, M., Axilbund, J., Buys, S., & Crawford, B. (2014). Genetics/familial high-risk assessment: Breast and Ovarian, Version 1.2014: National Comprehensive Cancer Network, Inc.
Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., & International Gastric Cancer Linkage, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 47(7), 436–444. doi:10.1136/jmg.2009.074237.
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., & Weitzel, J. N. (2009). Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250–1256. doi:10.1200/JCO.2008.16.6959.
Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J., & Houlston, R. S. (2006). Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clinical Cancer Research, 12(10), 3209–3215. doi:10.1158/1078-0432.CCR-06-0083.
Hilbers, F. S. M., Vreeswijk, M. P. G., van Asperen, C. J., & Devilee, P. (2013). The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clinical Genetics, 84(5), 407–414. doi:10.1111/Cge.12256.
Howlander, N. (2011). SEER cancer statistics review, 1975–2010. Bethesda: National Cancer Institute.
Kurian, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., Feunteun, J. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. Epub ahead of print.
Masciari, S., Van den Abbeele, A. D., Diller, L. R., Rastarhuyeva, I., Yap, J., Schneider, K., & Garber, J. E. (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315–1319. doi:10.1001/jama.299.11.1315.
Mauer, C. B., Pirzadeh-Miller, S. M., Robinson, L. D., & Euhus, D. M. (2014). The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genetics in Medicine, 16(5), 407–412.
Nelson, H.D., Fu, R., Griffin, J.C., Nygren, P., Smith, M.E., & Humphrey, L. (2009). Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med, 151(10), 703–715, W-226-735. doi: 10.7326/0003-4819-151-10-200911170-00147.
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical, O. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901. doi:10.1200/JCO.2009.27.0660.
Salmon, A., Amikam, D., Sodha, N., Davidson, S., Basel-Vanagaite, L., Eeles, R. A., & Peretz, T. (2007). Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clinical Oncology (Royal College of Radiologists), 19(7), 490–493. doi:10.1016/j.clon.2007.05.001.
Schrader, K. A., Masciari, S., Boyd, N., Wiyrick, S., Kaurah, P., Senz, J., & Huntsman, D. G. (2008). Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer, 7(1), 73–82. doi:10.1007/s10689-007-9172-6.
Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012). Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research, 18(2), 400–407. doi:10.1158/1078-0432.CCR-11-2283.
Conflict of Interest
Jennifer Doherty, Danielle C. Bonadies and Ellen T. Matloff declare that they have no conflict of interest.
Compliance with Ethical Standards
The authors of this manuscript do not have any conflicts of interest to declare. The authors did not collect funding for the development, execution or publication of this manuscript. The analysis involved the review of a dataset for Quality Improvement, met the criteria for IRB exception and therefore did not require IRB review per Yale policy. The research did not involve human subjects and therefore did not require informed consent.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doherty, J., Bonadies, D.C. & Matloff, E.T. Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice. J Genet Counsel 24, 683–687 (2015). https://doi.org/10.1007/s10897-014-9796-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-014-9796-2